NCT07519317Not yet recruiting
Dosing and Deployment Trial: A Home-based Optokinetic Treatment
Dosing and Deployment Trial: A Home-based Optokinetic Treatment for Ipsilesional Gaze Deviation
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
Several interventions exist for remediation of spatial neglect, but they have mixed evidence. Optokinetic stimulation is a bottom-up intervention; in other words, it is a stimulus-driven process, with Level A (strongest) evidence, and is recommended in clinical practice guidelines such as the American Heart Association's stroke guidelines. The studies currently published all use varing doses (number of sessions a week), did not assess the impact on mobility and risk of falls, and have not been implemented in the home setting. It is imperative to understand how to successfully implement this intervention at home, and learn how it will impact mobility in order to better support a large population of individuals living with chronic spatial neglect and who face barriers to accessing care because they require caregiver support to leave the home. This will be done using both qualitative and quantitative methods.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 2 Apr 2026
- Start date
- 4 Jan 2027
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Duke University
- Diseases
- Stroke
- NCT number
- NCT07519317
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 4 Jan 2027 to the primary completion date, 1 Feb 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- history of multiple strokes or neurological incidents (e.g., traumatic brain injury, seizures, or brain tumor),
- cognitive impairment as defined by the Blind-MoCA,
- the stroke survivor didn't consent
Other
- unable to communicate through spoken English, screened using the Aphasia Rapid Test (ART), as instructions for treatment and assessment tasks will be provided verbally in English,
- dependent in mobility- walking or wheelchair via medial chart,
- legally blind per medical chart,
- home located out of a 50-mile radius from Duke University, making it too costly for the frequent home visits, and
- no IGD present.
- not a care partner currently,
- can't speak English,
Who the study is looking for
- first and unilateral right brain damage stroke, confirmed by medical records,
- time post stroke \>6 months,
- moderate to severe SN, classified using the Catherine Bergego Scale (CBS) via the Kessler Foundation Neglect Assessment Process (KF-NAP),
- over age of 60 years, and
- IGD noted either on the KF-NAP or neuroimaging from medical records.
- a current care partner (defined as someone providing care and assistance) of a stroke survivor living with SN,
- English speaker,
- the stroke survivor they are caring for has been enrolled into the study.
Age in the registry: 60 years to 110 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.